Information Provided By:
Fly News Breaks for April 26, 2016
SRPT
Apr 26, 2016 | 08:48 EDT
Needham analyst Chad Messer lowered his price target for Sarepta to $20 from $53, following the FDA Advisory Committee vote against accelerated approval for its eteplirsen. The analyst views eteplirsen's chance for accelerated approval as diminished, but still expects full approval as early as next year. Messer adds that he continues to be a buyer of Sarepta's shares particularly on any sell-off. The firm has a Buy rating on the shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT